These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14978453)

  • 41. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings.
    Velligan DI; Prihoda TJ; Sui D; Ritch JL; Maples N; Miller AL
    J Clin Psychiatry; 2003 May; 64(5):524-31. PubMed ID: 12755654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
    J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of subjective and objective quality of life in outpatients with schizophrenia.
    Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
    Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment.
    Kaneda Y; Jayathilak K; Meltzer H
    Psychiatry Res; 2010 Jun; 178(1):57-62. PubMed ID: 20452677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
    Bret P; Bonnet F; Bret MC; Jaffré A
    Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
    Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
    Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
    Tollefson GD; Andersen SW; Tran PV
    Biol Psychiatry; 1999 Aug; 46(3):365-73. PubMed ID: 10435202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.
    Woodward ND; Purdon SE; Meltzer HY; Zald DH
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):457-72. PubMed ID: 15784157
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cognitive deficit in schizophrenia and its neurochemical basis.
    Breier A
    Br J Psychiatry Suppl; 1999; (37):16-8. PubMed ID: 10211135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
    DeQuardo JR; Tandon R
    J Psychiatr Res; 1998; 32(3-4):229-42. PubMed ID: 9793876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methodological issues in negative symptom trials.
    Marder SR; Daniel DG; Alphs L; Awad AG; Keefe RS
    Schizophr Bull; 2011 Mar; 37(2):250-4. PubMed ID: 21270473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New antipsychotics and schizophrenia: a review on efficacy and side effects.
    Serretti A; De Ronchi D; Lorenzi C; Berardi D
    Curr Med Chem; 2004 Feb; 11(3):343-58. PubMed ID: 14965236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
    Krakowski MI; Czobor P; Nolan KA
    J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cognitive effects and antipsychotic treatment.
    Kasper S; Resinger E
    Psychoneuroendocrinology; 2003 Jan; 28 Suppl 1():27-38. PubMed ID: 12504070
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The fragmentation of representational space in schizophrenia].
    Plagnol A; Oïta M; Montreuil M; Granger B; Lubart T
    Encephale; 2003; 29(5):401-11. PubMed ID: 14615689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.